Dyslipidemic Patients.
Argan oil prevents prothrombotic complications by lowering lipid levels and platelet aggregation, enhancing oxidative status in dyslipidemic patients from the area of Rabat (Morocco)
... Hypercholesterolemia and platelet hyperactivity are asso- ciated with an increased risk of adverse cardiovascular outcomes (coronary artery disease, hypertension). Argan oil is rich in unsaturated fatty acids, and also ...
9
Effects of bezafibrate on lipid and glucose metabolism in dyslipidemic patients with diabetes: the J-BENEFIT study
... in patients with type 2 diabetes ...in patients with type 2 diabetes ...in patients with impaired fasting glucose ...treating dyslipidemic patients with type 2 dia- betes if their ...
10
Low incidence of paradoxical reductions in HDL-C levels in dyslipidemic patients treated with fenofibrate alone or in combination with ezetimibe or ezetimibe/simvastatin
... mixed dyslipidemic patients receiving placebo, FENO monotherapy, or FENO in combination with eze- timibe (EZE) or EZE/simvastatin (SIMVA) ...FENO-treated patients ( n = 731) contributing to the ...
9
EFFECT OF PREBIOTIC - GUAR GUM SUPPLEMENTATION AMONG DYSLIPIDEMIC PATIENTS WITH OR WITHOUT HYPERGLYCEMIA
... categorize patients as per the National Cholesterol Education Programme (NCEP) Expert Panel on the Detection, Evaluation and Treatment of High Blood Cholesterol in Adults, Adult Treatment Panel III, 2001 ...
11
A Comparative Evaluation of the Efficacy and Side-Effect Profile of Simvastatin vs Atorvastatin in Dyslipidemic Patients
... mg, patients with coronary heart disease (CHD) alone and/or type 2 diabetes mellitus (T2DM) were randomized to ezetimibe 10 mg/simvastatin 20 mg (EZ/Simva) or simvastatin 40 ...diabetic patients (OR = ...
103
A study of correlation of C-Reactive Protein levels with carotid atherosclerotic plaques in dyslipidemic patients
... acid can lower homocysteine levels in many individuals. A substantial portion of the elderly population has only a marginal sufficiency of folate intake. Recommending a diet rich in folate or consumption of multivitamin ...
67
Original Article Clinical efficacy comparison of rosuvastatinwith atorvastatinin high-risk chinese dyslipidemic patients
... 90 patients with high-risk dyslipidemia who admitted in the fourth affiliated hospital of Harbin medical college from December 2013 to July ...these patients who met the following criteria were defined to ...
6
COMPARISON BAY LEAF (SYZYGIUM POLYANTHUM (WIGHT) WALP) EKSTRAKT WITH 400 MG AND 600MG DOSE ON LIPOPROTEIN(A) CONCENTRATION IN DYSLIPIDEMIC PATIENTS
... (a) patients and divided into 3 groups, group A (28 patients) received 20 mg / day simvastatin therapy, group B (29 patients) received atorvastatin 10 mg / day and group C (28 patients) ...
7
Factors Related to Adherence with Treatment of Dyslipidemic Patients on Continuous Use of Oral Lipid Lowering Drugs
... and patients with dyslipidemia, statin users in the city of Ribeirão Preto, São Paulo, ...of patients showed forgetfulness as the main cause for treatment interruption, followed by the difficulty of finding ...
7
A Comparative Study of Efficacy and Safety of Pitavastatin and Atorvastatin in Dyslipidemic Patients
... in patients with clinically evident coronary heart disease or a history of myocardial ...TGs). Patients in the highest quintile had a 63% higher rate of CVEs than patients in the lowest Quintile ...
129
Evaluation of efficacy and safety of fixed dose lovastatin and niacinER combination in Asian Indian dyslipidemic patients: a multicentric study
... All patients were recruited after obtaining written informed consent before their ...or dyslipidemic medication, or concurrent therapy with agents having potential to cause drug-drug interactions ...
7
Feeding Effect of Terminalia Arjuna and Guggul on the Biophysical Symptoms of Dyslipidemic Patients
... Cardio Vascular Disease (CVD) is a chronic, potentially debilitating disease and its prevalence is increasing in all populations in worldwide. Dyslipidemia and Hypertension are closely linked to the pathophysiology of ...
7
Apoa5 Q139X truncation predisposes to late onset hyperchylomicronemia due to lipoprotein lipase impairment
... While type 1 hyperlipidemia is associated with lipoprotein lipase or apoCII deficiencies, the etiology of type 5 hyperlipidemia remains largely unknown. We explored a new candidate gene, APOA5, for possible causative ...
9
Improvement of antioxidant status after Brazil nut intake in hypertensive and dyslipidemic subjects
... these patients related to duration of dis- ease, previous cardiovascular event and poor blood pres- sure control and serum lipids control, which may have influenced the ...and dyslipidemic patients’ ...
10
<p>Coenzyme q10 liquid supplementation in dyslipidemic subjects with statin-related clinical symptoms: a double-blind, randomized, placebo-controlled study</p>
... In the current study, we use a liquid CoQ10 formula- tion based on micro-sphere dispersion technology (Q- Factor) at a low dosage (100 mg/day) since previous studies 14–16 showed that its bioavailability was about 3- ...
9
Compliance to Dietary Counselling in Controlling Blood Lipid and its Barriers among Dyslipidemic Individuals
... among dyslipidemic individuals attending dietary follow-ups counselling in Diet Clinic of Universiti Kebangsaan Malaysia Medical Centre ...among dyslipidemic patients who received dietary ...improve ...
6
Pattern Recognition for Discrimination of Dyslipidemic States
... Abstract - The Centers for Disease Control and Prevention reported that the diseases of the heart, cancer, stroke, Alzheimer’s disease, and diabetes are among the top leading causes of deaths in the US for 2007. These ...
7
Cardiovascular risk assessment of dyslipidemic middle-aged adults without overt cardiovascular disease over the period of 2009–2016 in Lithuania
... Dyslipidemia and hypertension are the two most prevalent as well as most commonly co-existing major cardiovascular risk factors [9, 46]. Abnormal lipid levels are one of the earliest metabolic disturbances in adults with ...
9
Comparison of the efficacy and safety of atorvastatin monotherapy and atorvastatin plus fenofibrate combination therapy in combined dyslipidemia
... The atorvastatin plus fenofibrate combination therapy(Group B) resulted in statistically significant reduction in the serum levels of TC (15.95%), TG (34.02%), and LDL-C (26.11%)24 weeks post treatment (Table 2). These ...
6
Transcriptome-based identification of antioxidative gene expression after fish oil supplementation in normo- and dyslipidemic men
... and dyslipidemic men were recruited by several advertisements and study placards in ...ten dyslipidemic (TC > 200 mg/dl; LDL-C> 130 mg/dl; TG > 150 mg/ml) men, aged between 29 and 51 years, were ...
13